Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867005957308940288 |
|---|---|
| author | Sara Rahavi‐Ezabadi Sheng Zhou Stella E. Lee Elisabeth Ference Anthony Magit Shelby Leuin Kawthar Mohamed Nima Rezaei Vijay A. Patel |
| author_facet | Sara Rahavi‐Ezabadi Sheng Zhou Stella E. Lee Elisabeth Ference Anthony Magit Shelby Leuin Kawthar Mohamed Nima Rezaei Vijay A. Patel Sara Rahavi‐Ezabadi Sheng Zhou Stella E. Lee Elisabeth Ference Anthony Magit Shelby Leuin Kawthar Mohamed Nima Rezaei Vijay A. Patel |
| collection | Wiley Open Access |
| contents | Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review Sara Rahavi‐Ezabadi Sheng Zhou Stella E. Lee Elisabeth Ference Anthony Magit Shelby Leuin Kawthar Mohamed Nima Rezaei Vijay A. Patel Otolaryngology–Head and Neck Surgery AbstractObjectiveProvide clinicians with current evidence for biologic therapy in children with chronic rhinosinusitis with nasal polyposis (CRSwNP).Data SourcesPubMed, MEDLINE, Cochrane, and clinical trial registries.Review MethodsKey search terms related to biologic therapy in pediatric CRSwNP were identified via a structured query of current medical literature and clinical trial databases.ConclusionsThere is a dearth of active clinical trials and research studies for biologics targeting pediatric CRSwNP. There is an ongoing compassionate‐use clinical trial involving Dupilumab for children with nasal polyps as well as only 1 published work specifically focused on Dupilumab for pediatric CRSwNP in the setting of aspirin‐exacerbated respiratory disease.Implications for PracticeFor children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease. 10.1002/ohn.717 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/ohn.717 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_ohn_717 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review Sara Rahavi‐Ezabadi Sheng Zhou Stella E. Lee Elisabeth Ference Anthony Magit Shelby Leuin Kawthar Mohamed Nima Rezaei Vijay A. Patel Otolaryngology–Head and Neck Surgery Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review Sara Rahavi‐Ezabadi Sheng Zhou Stella E. Lee Elisabeth Ference Anthony Magit Shelby Leuin Kawthar Mohamed Nima Rezaei Vijay A. Patel Otolaryngology–Head and Neck Surgery AbstractObjectiveProvide clinicians with current evidence for biologic therapy in children with chronic rhinosinusitis with nasal polyposis (CRSwNP).Data SourcesPubMed, MEDLINE, Cochrane, and clinical trial registries.Review MethodsKey search terms related to biologic therapy in pediatric CRSwNP were identified via a structured query of current medical literature and clinical trial databases.ConclusionsThere is a dearth of active clinical trials and research studies for biologics targeting pediatric CRSwNP. There is an ongoing compassionate‐use clinical trial involving Dupilumab for children with nasal polyps as well as only 1 published work specifically focused on Dupilumab for pediatric CRSwNP in the setting of aspirin‐exacerbated respiratory disease.Implications for PracticeFor children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease. 10.1002/ohn.717 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review |
| topic | Otolaryngology–Head and Neck Surgery |
| url | https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1002/ohn.717 |